Debbie Law currently serves as CSO of Xaira. Prior to joining Xaira, she was Senior Vice President of Nonclinical Research and Discovery Biotherapeutics at Bristol Myers Squibb. She has over 25 years of experience in drug development in both pharma and biotech, specializing in biologics (monoclonal antibodies/fragments/novel technologies) for use as therapeutics across disease areas including immuno-oncology, oncology, and autoimmunity. With a focus on driving preclinical programs from target discovery and validation to testing and transition into clinical stages, she has been fortunate to have been involved in programs resulting in approved biologics, including pembrolizumab (Keytruda™) and elotuzumab (Empliciti™). She joined BMS in 2020 as SVP of the Tumor Microenvironment Thematic Research Center, where her team helped progress multiple assets, both large and small molecules, to the clinic. Prior to joining BMS, she held positions including CSO of Jounce Therapeutics; Vice President of Immuno-oncology Discovery at Merck; Vice President of Discovery Biologics at Merck; CSO of Ablynx n.v, the Nanobody™ company; and Vice President of Research at PDL Biopharma/Protein Design Labs. Debbie received her B.Sc in immunology from the University of Glasgow and her D.Phil. in immunology from the University of Oxford. She pursued post-doctoral research at UCSF in San Francisco.